The administration of 2-Deoxy-D-glucose (2-DG), an inhibitor of glycolysis, clearly normalized the SLE-like pathological characteristics in Trex1–/–CD4+ T cells immunized BM12 mice (Fig. 2A–C). The gene discussed is TREX1; the disease is systemic lupus erythematosus.